Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Official title

A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

Overview

This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.

Detailed description

PRIMARY OBJECTIVES:

I. To investigate the optimal dose of multi-antigen CMV-modified vaccinia ankara vaccine (Triplex) in CMV-positive pediatric patients receiving human leukocyte antigen (HLA) matched, mismatched, or haploid-identical hematopoietic cell transplantation (HCT). (Phase I) II. To evaluate the safety profile of Triplex in this patient population. (Phase I) III. To determine if Triplex reduces the frequency of CMV events when compared to historical data. (Phase II)

SECONDARY OBJECTIVES:

I. To characterize CMV reactivation and disease by assessing: time to CMV reactivation, duration of viremia, recurrence of viremia, incidence of late CMV viremia/disease (defined as \> 100 days and =\< 365 days post HCT), use of anti-viral drugs triggered by rising CMV viremia or viremia \>= 3750 IU/mL, cumulative number of CMV specific antiviral treatment days.

II. To evaluate the impact of Triplex on transplant related outcomes by assessing the incidence of acute and chronic graft versus host disease (GVHD), relapse, non-relapse mortality (NRM), all-cause mortality, infections.

III. To investigate the impact of Triplex on cellular immunity by investigating: the level, function and kinetics of CMV-specific T-cell immunity, the changes in adaptive natural killer (NK) cell population and highly cytotoxic memory NKG2C+ NK cells, and changes in GVHD biomarkers.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive multi-antigen CMV-modified vaccinia ankara vaccine intramuscularly (IM) on days 28 and 56 post-HCT.

After completion of study treatment, patients are followed up for up to 270 or 365 days.

Interventions

• Other Laboratory Biomarker Analysis
  Correlative studies
• Biological Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
  Given IM

Primary outcome measures

• Optimal dose (Phase I) [Time frame: Up to 1 year]
• Incidence of adverse events (Phase I) [Time frame: Up to 1 year]
• Cytomegalovirus (CMV) events (reactivation >= 1250 IU/mL), or viremia treated by anti-viral therapy, or detection of CMV by histology (Phase II) [Time frame: Prior to day 100 post-hematopoietic cell transplantation (HCT) or viremia treated by anti-viral therapy, or detection of CMV by histology]
• Non-relapse mortality [Time frame: At 100 days post-HCT]
• Severe (grade 3-4) acute graft versus host disease (aGVHD) [Time frame: Within 2 weeks from each vaccination]
• Incidence of grade 3-4 adverse events [Time frame: Within 2 weeks from each vaccination]

Secondary outcome measures (12)

• Time-to viremia [Time frame: Number of days from transplant to the date of > 1250 IU/mL, assessed up to 1 year]
• Duration of viremia [Time frame: Up to 1 year]
• Incidence of late CMV viremia [Time frame: > 100 and =< 365 days post-HCT]
• Use of antiviral drugs (triggered by rising CMV viremia or viremia >= 3,750 IU/ml) [Time frame: Up to 1 year, rising CMV viremia or viremia >= 3,705]
• Cumulative number of CMV specific antiviral treatment days [Time frame: Up to 1 year]
• Time to engraftment [Time frame: Up to 1 year]
• Incidence of acute graft versus host disease (aGVHD) [Time frame: Up to 1 year]
• Chronic GVHD (cGVHD) [Time frame: Up to 1 year]
• Relapse defined by bone marrow and/or imaging studies [Time frame: Up to 1 year]
• Non-relapse mortality [Time frame: Up to 1 year]
• All-cause mortality [Time frame: Up to 1 year]
• Infections [Time frame: Up to 1 year]

Eligibility criteria

Inclusion criteria

• All subjects (or their guardians) must have the ability to understand and the willingness to sign a written informed consent; age appropriate assent will be obtained per institutional guidelines; to allow non-English patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible
• Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
• Planned allogenic (allo)-HCT, with 9/10 or 10/10 (A, B, C, DRB1, DQB1) high/intermediate resolution HLA donor allele matching and with no T-cell depletion of graft
• Planned related HCT with molecular 3/6 HLA donor allele matching (haploidentical) (for phase I only)
• CMV seropositive at the time of HCT
• Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
• Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
• Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV); if hepatitis B virus (HBV) core seropositive, absence of HBV deoxyribonucleic acid (DNA) within 2 months of registration
• Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

Exclusion criteria

• TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT)
• Any prior investigational CMV vaccine
• Anti-CMV therapy in the last 6 months
• Live attenuated vaccines
• Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus \[HPV\]) or killed vaccine (e.g. influenza, pneumococcal)
• Allergy treatment with antigens injections
• Alemtuzumab, cyclophosphamide, ATG or any equivalent in vivo T-cell depleting agent; Note: Pre-transplant ATG is permitted
• Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valine (VAL), FOS, Cidofovir, CMX-001, maribavir; acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)
• Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment; intravenous immunoglobulin therapy (IVIG) is allowed
• Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
• Other medications that might interfere with the evaluation of the investigational product
• Patients with congenital immune deficiency
• Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible, the exception to this is patients with aplastic anemia, who are eligible
• Pregnant women and women who are lactating; CMV-MVA Triplex risks to pregnant women are unknown; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study
• Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/psychological issues, etc
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issue related to feasibility/logistics)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Supportive care

Study locations

United States · 1 center

• City of Hope Medical Center — Duarte

Identifiers

NCT: NCT03354728 · 17236 · NCI-2017-02046 · 17236

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗